Pemvidutide — living evidence map

Summary

Pemvidutide is a GLP-1 and glucagon dual receptor agonist; in a 12-week randomized trial in 94 people with metabolic dysfunction-associated steatotic liver disease, weekly injections cut liver fat by 46.6% to 68.5% from baseline against 4.4% on placebo. · pmid:39002641

Identity

No public registry record is shown for this page: PubChem gave no record that proves it is this substance.

Where the evidence actually sits

Proportion of the 1 claim about Pemvidutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Pemvidutide yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

1. Approved-label dose · a resolved regulatory document names a labelled dose

   nothing resolved on this rung

2. Studied human doses · resolved human studies at the established tier

   nothing resolved on this rung

3. Observational evidence · resolved human data at the emerging tier: thin, or contested
   • Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. · pmid 39002641 · 2025
4. Community-reported protocols · protocol propositions from distinct members, counted once per human

   nothing resolved on this rung

5. Preclinical evidence · resolved animal, cell or mechanistic work

   nothing resolved on this rung

1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.